Clal Biotech (CBI) Stock Statistics & Valuation Metrics

Clal Biotech has a market cap or net worth of 48.78M. The enterprise value is 93.55M.

Clal Biotech has 156,846,200 shares outstanding. The number of shares has decreased by -2.65% in one year.

Clal Biotech’s return on equity (ROE) is -0.31 and return on invested capital (ROIC) is -6.48%.

The current PE Ratio of Clal Biotech is -2.05. Clal Biotech’s PEG ratio is 0.00.

In the last 12 months, Clal Biotech had revenue of 104.00K and earned -31.05M in profits. Earnings per share was -0.20.

In the last 12 months, operating cash flow was -8.51M and capital expenditures -5.00K, giving a free cash flow of -8.52M billion.

Clal Biotech pays an annual dividend of 22.372, resulting in a dividend yield of ―

Clal Biotech upcoming earnings date is Nov 22, 2021, TBA (Confirmed).

Clal Biotech as a current ratio of 2.21, with Debt / Equity ratio of 56.90%

In the past 12 months, Clal Biotech has paid 0.00 in taxes.

Clal Biotech EV to EBITDA ratio is -3.89, with an EV/FCF ratio of -10.98.

Clal Biotech has 13.36M in cash and marketable securities with 35.76M in debt, giving a net cash position of 22.40M billion.

Gross margin is 0.00%, with operating margin of -9789.42%, and net profit margin of -29856.73%.

The average price target for Clal Biotech is ―, which is 11.43% higher than the current price. The consensus rating is ―